ProVise Management Group LLC boosted its holdings in Zoetis Inc (NYSE:ZTS) by 13.5% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 9,283 shares of the company’s stock after buying an additional 1,104 shares during the period. ProVise Management Group LLC’s holdings in Zoetis were worth $668,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Janus Henderson Group PLC raised its holdings in Zoetis by 1.5% in the third quarter. Janus Henderson Group PLC now owns 5,893,853 shares of the company’s stock valued at $375,792,000 after buying an additional 84,767 shares during the period. Legal & General Group Plc raised its holdings in Zoetis by 1.5% in the third quarter. Legal & General Group Plc now owns 2,400,106 shares of the company’s stock valued at $153,025,000 after buying an additional 34,747 shares during the period. Frontier Capital Management Co. LLC raised its holdings in Zoetis by 1.3% in the third quarter. Frontier Capital Management Co. LLC now owns 2,140,589 shares of the company’s stock valued at $136,484,000 after buying an additional 26,902 shares during the period. Bessemer Group Inc. raised its holdings in Zoetis by 231,590.8% in the fourth quarter. Bessemer Group Inc. now owns 2,117,654 shares of the company’s stock valued at $152,557,000 after buying an additional 2,116,740 shares during the period. Finally, Swiss National Bank raised its holdings in Zoetis by 0.7% in the third quarter. Swiss National Bank now owns 1,809,280 shares of the company’s stock valued at $115,360,000 after buying an additional 12,900 shares during the period. Hedge funds and other institutional investors own 93.72% of the company’s stock.
Shares of Zoetis Inc (NYSE ZTS) opened at $73.24 on Wednesday. The stock has a market cap of $35,690.00, a P/E ratio of 38.55, a PEG ratio of 1.60 and a beta of 1.07. Zoetis Inc has a 12 month low of $52.00 and a 12 month high of $80.13. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, January 19th will be paid a dividend of $0.126 per share. The ex-dividend date is Thursday, January 18th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.69%. This is a positive change from Zoetis’s previous quarterly dividend of $0.11. Zoetis’s dividend payout ratio (DPR) is currently 26.32%.
Several research analysts recently commented on the stock. BMO Capital Markets set a $78.00 price target on shares of Zoetis and gave the company a “hold” rating in a report on Monday, January 22nd. Piper Jaffray Companies restated a “buy” rating and issued a $86.00 price target on shares of Zoetis in a report on Thursday, January 18th. Jefferies Group reiterated a “buy” rating and set a $89.00 price objective on shares of Zoetis in a research note on Tuesday, January 16th. Zacks Investment Research lowered shares of Zoetis from a “hold” rating to a “sell” rating and set a $83.00 price objective on the stock. in a research note on Saturday, January 13th. Finally, Cantor Fitzgerald set a $85.00 price objective on shares of Zoetis and gave the company a “buy” rating in a research note on Thursday, January 11th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have given a buy rating to the company. Zoetis has an average rating of “Buy” and an average target price of $73.72.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/14/provise-management-group-llc-boosts-position-in-zoetis-inc-zts.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.